NEW YORK, NY / ACCESSWIRE / January 22, 2025 / The following statement is being issued by Levi & Korsinsky, LLP:To: All Persons or Entities ...
Mizuho Securities analyst Uy Ear maintained a Hold rating on Revance Therapeutics (RVNC – Research Report) yesterday and set a price target of ...
Securities updated its stance on Revance Therapeutics (NASDAQ:RVNC) stock by increasing the price target to $3.65 from the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback